Authored By: Sarah
26 Jun 2024

 Breast Cancer Therapeutics Market Size to grow by USD 15.64 billion between 2024-2028

According to a research report “ Breast Cancer Therapeutics Market” by Disease Type (Invasive breast cancers, Ductal carcinoma in situ) Therapy (Targeted therapy, Hormonal therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 15.64 billion, at a CAGR of  8.4% during the forecast period. In the global health landscape, breast cancer represents a significant challenge, being the most frequently diagnosed cancer among women and the fifth leading cause of mortality. According to the CDC, approximately 237,000 cases of breast cancer are diagnosed annually in the US, with about 41,000 resulting in fatalities for women, and 450 for men. Despite advancements in early diagnosis, the risk of developing breast cancer remains prevalent, with an estimated 2,100 new cases reported among American women and men each year. The high incidence and mortality rates necessitate continuous research and development of innovative therapeutic solutions to combat this disease.

Browse market data tables, figures, and in-depth TOC on “Breast Cancer Therapeutics Market” by Disease Type (Invasive breast cancers, Ductal carcinoma in situ) Therapy (Targeted therapy, Hormonal therapy, Chemotherapy) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Disease Type, the Invasive breast cancers segment is projected to dominate the market size in 2024

In the realm of oncology, targeted therapeutics represent a significant advancement in cancer treatment. These therapies specifically target proteins that contribute to the uncontrolled growth, division, and dissemination of cancer cells. Targeted therapeutics encompass both small-molecule drugs and monoclonal antibodies (MAbs), the latter being proteins engineered in laboratories to recognize and bind to distinct targets on cancer cells. Monoclonal antibodies function by tagging cancer cells for destruction and inhibiting signals that instigate their unregulated proliferation. The anticipated approvals of novel targeted therapeutics during the forecast period serve as a major catalyst for market expansion.

By Therapy, Targeted therapy  segment is expected to hold the largest market size for the year 2024

Invasive ductal carcinoma, or IDC, is the most prevalent form of breast cancer, accounting for approximately 80% of diagnosed cases. This type of cancer is characterized by the infiltration of the breast's fibrous or fatty tissue by malignant cells, originating from the lactiferous ducts. Key symptoms include breast swelling, skin irritation, pain, and nipple abnormalities such as discharge, pain, redness, and dimpling. Genetic mutations in BRCA1, BRCA2, and ErbB2 genes, as well as environmental and lifestyle factors like smoking, poor nutrition, and prior chest radiation therapy, significantly increase the risk of developing IDC.

North America is forecasted to hold the largest market size by region in 2024

The North American breast cancer therapeutics market is experiencing significant growth, driven by the presence of reimbursement schemes in countries like the US and Canada. In the US, the Centers for Medicare & Medicaid Services (CMS) covers the cost of breast cancer treatment and diagnosis, including Trastuzumab and IBRANCE. The CMS has also implemented value-based care models to manage therapeutic expenses. Approximately 264,000 breast cancer cases are diagnosed annually in American women, and 2,400 cases are diagnosed in men. This substantial patient base, coupled with supportive reimbursement policies, fuels the market expansion in the region.

The Breast Cancer Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Clovis Oncology Inc.
  • Daiichi Sankyo Co. Ltd.
  • Eisai Co. Ltd.
  • Eli Lilly and Co.
  • Exelixis Inc.
  • F. Hoffmann La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck and Co. Inc.
  • Novartis AG
  • PerkinElmer Inc
  • Pfizer Inc.
  • Puma Biotechnology Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Breast cancer is a major health concern for females worldwide, with symptoms including lumps, red patches, swelling, pain, and breathing problems due to the spread of breast cancer cells to the lungs. These cells can also affect the lymph nodes, bones, and milk-producing lobules and milk ducts, leading to breast cancer mortality and diagnoses. Hormonal therapies, medications, surgical tumor removal, and various therapeutic approaches are used to treat breast cancer. Hormonal therapies target the hormones that fuel breast cancer growth, while oncology drugs/therapeutics like immunotherapy, targeted therapy, hormone therapy, radiation therapy, and chemotherapy attack breast cancer cells directly. Artificial intelligence and screening programs play a crucial role in early detection, while breast cancer awareness campaigns educate the public on risk factors and prevention methods. Proteins are also being studied as potential targets for new breast cancer treatments. The global breast cancer therapeutics market is expected to grow significantly due to the increasing prevalence of breast cancer and the development of new and effective therapeutic options.

Market Research Overview

Title: Breast Cancer Therapeutics Market: Trends, Therapies, and Key Players Breast cancer is a major health concern for females worldwide. The therapeutics market for breast cancer includes various treatment modalities such as hormonal therapy, targeted therapy, immunotherapy, radiation therapy, and chemotherapy. The market is segmented based on cancer type, including HER2-positive, triple-negative, and hormone receptor-positive. Factors such as family history, menopause, hormone problems, alcohol intake, obesity, and genetic mutations increase the risk of breast cancer. Early detection through screening programs and breast cancer awareness campaigns are crucial for improving recovery rates. Key players in the breast cancer therapeutics market include online pharmacies and hospital pharmacies. Hospitals visits for surgical tumor removal, hormonal therapies, and oncology drugs/therapeutics like Herceptin, biosimilars, and hormonal therapies are common. Breast cancer affects the milk-producing lobules and milk ducts, causing symptoms like lumps, red patches, nipple discharge, pain, swelling, lymph node involvement, breathing problems, and bone metastasis. The market is expected to grow due to the increasing number of breast cancer diagnoses and mortality rates. Government support, advancements in artificial intelligence, and the development of new therapeutic approaches like immunotherapy and targeted therapy are driving market growth. Morbidity and survival probabilities vary based on early-stage diagnoses and mortality rates. The market's future looks promising with ongoing research and advancements in breast cancer treatments.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio